Brokerages expect that VERONA PHARMA P/S (NASDAQ:VRNA) will report earnings of ($0.61) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for VERONA PHARMA P/S’s earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.73). VERONA PHARMA P/S posted earnings per share of $0.06 in the same quarter last year, which suggests a negative year-over-year growth rate of 1,116.7%. The company is scheduled to report its next earnings results on Tuesday, August 6th.
Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.04.
VRNA stock opened at $6.14 on Tuesday. VERONA PHARMA P/S has a 1 year low of $5.52 and a 1 year high of $17.16.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in VERONA PHARMA P/S during the first quarter valued at $76,000. IHT Wealth Management LLC purchased a new position in VERONA PHARMA P/S during the first quarter valued at $113,000. Wedbush Securities Inc. purchased a new position in VERONA PHARMA P/S during the fourth quarter valued at $127,000. Aisling Capital Management LP purchased a new position in VERONA PHARMA P/S during the fourth quarter valued at $4,281,000. Finally, venBio Partners LLC purchased a new position in VERONA PHARMA P/S during the first quarter valued at $5,688,000. Institutional investors own 57.49% of the company’s stock.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Recommended Story: Why is Cost of Capital Important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.